연구성과로 돌아가기

2021 연구자 정보 (39 / 1146)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Lee, YeonJu
(Lee, Y) ⓘ 		Sanofi Korea, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer ⓘ SCIE ⓘ 2.2 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Lu, Yen-Shen
(Lu, YS) ⓘ 		ⓘ AAO-4015-2020
Shen, Yuchen ⓘ
ⓘ 		[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. ⓘ SCIE ⓘ 2.2 ONCOLOGY ⓘ ⓘ
Nayyar, Anand
(Nayyar, A) ⓘ 		제1저자 Duy Tan Univ, Da Nang, Vietnam ⓘ F-3732-2015
Nayyar, Anand ⓘ
ⓘ 		[JCR상위 2.2] Social, mobile, analytic and cloud technologies: Intelligent Computing for future smart cities ⓘ SCIE ⓘ 2.2 CONSTRUCTION & BUILDING TECHNOLOGY;ENERGY & FUELS;GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY ⓘ anandnayyar@duytan.edu.vn;sara.paiva@estg.ipvc.pt;Paul.editor@gmail.com;akshikumar@dce.ac.in; ⓘ
Noh, Sung Hoon
(Noh, SH) ⓘ 		Yonsei Univ Hlth Syst, Gangnam Severance Hosp, Dept Surg, Seoul, South Korea ⓘ
ⓘ 		0000-0003-4386-6886
Noh, Sung Hoon ⓘ 		[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer ⓘ SCIE ⓘ 2.2 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
O'Connell, Joseph P.
(O'Connell, JP) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. ⓘ SCIE ⓘ 2.2 ONCOLOGY ⓘ ⓘ
O'Shaughnessy, Joyce
(O'Shaughnessy, J) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. ⓘ SCIE ⓘ 2.2 ONCOLOGY ⓘ ⓘ
Oh, Sang Cheul
(Oh, SC) ⓘ 		Korea Univ, Dept Internal Med, Guro Hosp, Seoul, South Korea
Korea Univ, Coll Med, Dept Internal Med, Div Hematol & Oncol, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer
[JCR상위 19.8] Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab ⓘ 		SCIE ⓘ 2.2 ONCOLOGY
GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY ⓘ 		ykkang@amc.seoul.kr;
nboku@ncc.go.jp; ⓘ
Paiva, Sara
(Paiva, S) ⓘ 		교신저자 Inst Politecn Viana do Castelo, Viana Do Castelo, Portugal ⓘ O-9328-2015
Paiva, Sara ⓘ 		0000-0002-0041-8939
Paiva, Sara ⓘ 		[JCR상위 2.2] Social, mobile, analytic and cloud technologies: Intelligent Computing for future smart cities ⓘ SCIE ⓘ 2.2 CONSTRUCTION & BUILDING TECHNOLOGY;ENERGY & FUELS;GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY ⓘ anandnayyar@duytan.edu.vn;sara.paiva@estg.ipvc.pt;Paul.editor@gmail.com;akshikumar@dce.ac.in; ⓘ
Panasci, Lawrence C.
(Panasci, LC) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. ⓘ SCIE ⓘ 2.2 ONCOLOGY ⓘ ⓘ
Park, ChoHyun
(Park, C) ⓘ 		Catholic Univ Korea, Coll Med, Dept Surg, Seoul St Marys Hosp, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer ⓘ SCIE ⓘ 2.2 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Park, Young-Kyu
(Park, YK) ⓘ 		Chonnam Natl Univ, Dept Surg, Med Sch, Hwasun, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer ⓘ SCIE ⓘ 2.2 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Rathore, M. Mazhar
(Rathore, MM) ⓘ 		제1저자 교신저자 Hamad Bin Khalifa Univ, Div Informat & Comp Technol, Coll Sci & Engn, Doha, Qatar ⓘ
ⓘ 		0000-0002-0701-9850
Rathore, Muhammad Mazhar ⓘ 		[JCR상위 2.2] Smart traffic control: Identifying driving-violations using fog devices with vehicular cameras in smart cities ⓘ SCIE ⓘ 2.2 CONSTRUCTION & BUILDING TECHNOLOGY;ENERGY & FUELS;GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY ⓘ mrathore@hbku.edu.qa;paul.editor@gmail.com;smrho@cau.ac.kr;muradkhan23@gmail.com;svimalphd@gmail.com;syed.shah@ut.ee; ⓘ
Recalde, Sabela
(Recalde, S) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. ⓘ SCIE ⓘ 2.2 ONCOLOGY ⓘ ⓘ
Rugo, Hope S.
(Rugo, HS) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. ⓘ SCIE ⓘ 2.2 ONCOLOGY ⓘ ⓘ
Schwartzberg, Lee S.
(Schwartzberg, LS) ⓘ 		제1저자 ⓘ
ⓘ
ⓘ 		[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. ⓘ SCIE ⓘ 2.2 ONCOLOGY ⓘ ⓘ
페이지 이동: